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A B S T R A C T
Increased serum bilirubin levels in patients with Gilbert syndrome (GS) are caused by reduction of hepatic activity of
bilirubin glucuronosyltranferase to about 30% of normal. UGT1A1 genetic polymorphism with absent or very low biliru-
bin UDP-glucuronosyltransferase (B-UGT) activity is associated with Gilbert’s syndrome (GS) and other hyperbiliru-
binemias. The genetic basis of GS is the insertion of two additional TA nucleotides (resulting in seven repeats of TA) in
the TATAA box, present in proximal promoter of UGT1A1 gene. This study included 323 Croatian pre-scholars, includ-
ing 164 boys and 159 girls. Statistical analysis showed significant difference for total bilirubin concentration between
different genotypes (p<0.001). Also, statistically significant difference for total bilirubin concentration was emphasized
between genotypes 6/6 and 7/7 (p<0.001) as well as 6/7 and 7/7 (p<0.001). Higher total plasma bilirubin concentrations
are significantly correlated with 7/7 genotype which is present in 9.8 % of population studied.
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Introduction
Gilbert syndrome was described for the first time in
1901 by French physicians Gilbert and Lereboullet. It is
a hereditary chronic disorder with 3–7% prevalence in
general population. The main characteristics of the synd-
rome are mild unconjugated hiperbilirubinemia, absence
of bilirubinuria, hemolysis or functional liver disorder1.
Unconjugated bilirubin is a result of hem catabolism
from hemoglobin and other hemoproteins. In hepato-
cytes the conjugation of nonpolar and compounds poorly
soluble in water is a process of biotransformation impor-
tant for detoxification and excretion of those compounds
in bile. The UDP-glucuronosyltransferases (UGTs) are a
family of enzymes responsible for their glucuronidation.
Conjugation of bilirubin with glucuronide is catalysed by
the hepatic enzyme bilirubin UDP-glucuronosyltrans-
ferase (B-UGT). The result of glucuronidation is the for-
mation of bilirubin mono- and di-glucuronide which are
excreted into bile1. Increased serum bilirubin levels in
patients with Gilbert syndrome (GS) are caused by re-
duction of hepatic activity of bilirubin glucuronosyltranf-
erase to about 30% of normal2,3.
UGT1 gene encodes 13 different UDP-glucuronosyl-
transferase genes. It is located on chromosome 2q37 and
spreads 218 kb in length. It has a complex structure com-
posed of 4 common exons (2–5) and 13 aminoterminal
exons (1A1–1A13)2,4. Physiologically important isoform
for bilirubin conjugation is coded by exon 1A1 and com-
mon exons 2–54.
UGT1A1 genetic polymorphisms without or very low
B-UGT activity are associated with Gilbert’s syndrome
and other hyperbilirubinemias such as and Criggler-
-Najjar’s syndrome type I and type II5.
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The genetic basis of GS is the insertion of two addi-
tional TA nucleotides in the TATAA box present in the
proximal promoter part of UGT1A1 gene. As a result of
the insertion UGT1A1*28 allele is formed. The tran-
scription of the preformed gene is reduced to 20% and
bilirubin glucuronidation decreased, in homozygous vari-
ants even by 80%2. However, smaller percentage of ho-
mozygous subjects has normal bilirubin serum concen-
tration which indicates that mutation in the promoter
region of this gene is not the only cause for manifestation
of the syndrome3. Additional factors responsible for syn-
drome manifestation could be reduced lifetime of red
blood cells or defects in hepatic transport mechanism
causing decreased hepatic uptake of unjconjugated bili-
rubin6.
The aim of our study was to explore genotype fre-
quencies of the UDP-glucuronosyltransferase 1A1 gene
polymorphism in the TATAA box in the population of
Croatian pre-scholars in order to define early risk for GS
and other hyperbilirubinemias. We also investigated the
association between different genotypes and plasma bili-
rubin concentrations.
Materials and Methods
Study subjects
Study subjects were recruited among Croatian pre-
-scholars in the city of Pula, who underwent routine
medical examination for primary school registration.
The study included 323 pre-scholars with of median age
6 ± 0.5 (155 girls and 164 boys). The blood samples were
collected in June 2006 during the routine medical exami-
nations for primary school registration at the division for
school medicine in Pula General Hospital. Whole blood
was collected into EDTA Vacutainer tubes (Terumo Eu-
rope, Belgium) for DNA extraction and plasma separa-
tion. Considering the fact that examinees were under
age, parents were asked to give an informed consent for
children to participate in the study. Study was approved
by the Ethical Committee of Pula General Hospital and
Medical School University of Zagreb.
Determination of plasma bilirubin concentration
Total plasma bilirubin concentration was determined
by standard photometric method with diazo reagents on
a Hitachi 717 (Roche, Switzerland). Samples with conju-
gated bilirubin measured values higher than 6 mmol/L
were excluded from statistical analysis.
DNA analysis
DNAwas isolated by the salting out method7. In order
to analyze TA insertion in the promoter region of the
UGT1A1 (TATAA box) amplification product was gener-
ated by polymerase chain reaction (PCR) using primers
to amplify 253–255 bp long fragment, as described pre-
viously8. PCR was performed in a total volume of 25 mL
containing 8 ng of template DNA, 0.2 mM of deoxy-
nucleotides, 1.5 mM buffer with MgCl2, 0.2 mM of each
primer and 0.75 units of Fast start Taq polymerase
(Roche Diagnostics, Switzerland). Amplification was per-
formed using GeneAmp PCR System 2700 (Applied Bio-
systems, USA). The PCR conditions included 25 cycles
with the temperature profiles as follows: denaturation at
95° for 30 seconds, annealing at 62° for 40 seconds and
extension at 72° for 40 seconds between initial denatur-
ation at 95° for 5 minutes and final extension at 72° for 5
minutes.
The amplification was confirmed by 1.5% agarose gel
electrophoresis. Amplified fragments were resolved on
Spreadex EL 500 gels (Elchrom Scientific, Switzerland)
using Elchrom Submerged Gel Electrophoresis System
(Elchrom Scientific, Switzerland). Gels were run at 144
Volts for 4 h, than stained with SybrGreen I (Roche Diag-
nostics, Switzerland) for 45 min. and destained with
Destaining solution (Elchrom Scientific, Switzerland) for
20 min. Genotypes were assigned as follows: homozygous
for A(TA) 6TAA allele (6/6), heterozygous with one
A(TA)6TAA and one A(TA)7TAA allele (6/7) and homozy-
gous for A(TA)7TAA allele (7/7) (Figure 1).
Statistical analysis
Statistical analysis was performed using a StatSoft,
Inc. (1984–2005) STATISTICA version 7.1. Genotype fre-
quencies were calculated by counting. Chi-square test
was used for determination of Hardy-Weinberg equilib-
rium. Bilirubin concentrations between different geno-
types were compared using nonparametric Kruskal-
-Wallis and Mann-Whitney test. Multivariate analysis
(MANOVA) with gender as covariate was used for testing
the effect of UGT1A1 promoter polymorphism on total
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Fig. 1. Electrophoresis of the PCR-amplified fragments, 253–255
bp long in Spreadex EL 500 (1–50 bp marker; 2, 3, 4, 6, 8-geno-
type 6/7; 5-genotype 7/7; 7, 9, 10-genotype 6/6).
bilirubin concentration. Total bilirubin concentrations
were log-transformed for testing with MANOVA.
Results
In 323 samples the frequencies of genotypes 6/6, 6/7
and 7/7 genotype were 38.4%, 47.9% and 9.8%, respec-
tively. Genotype frequencies were in Hardy-Weinberg
equilibrium. Total bilirubin concentrations in all three
genotypes are reported in Table 1 and Figure 2. Bilirubin
concentration did not show normal distribution (test of
homogeneity of variances, p<0.001). Statistical analysis
showed significant difference for total bilirubin concen-
tration between different genotypes (p<0.001). Also, sta-
tistically significant difference for total bilirubin concen-
tration was emphasized between genotypes 6/6 and 7/7
(p<0.001) as well as 6/7 and 7/7 (p<0.001). Multivariate
analysis showed that there were no changes in statistical
significance after corrections by gender.
Out of 323 subjects only 6 had total bilirubin concen-
tration higher than the upper limit of the plasma total
bilirubin reference interval (³19 mmol/L). Five of them
were genotyped as 7/7 with median plasma bilirubin con-
centrations 23.9 (minimum: 21.3; maximum: 34.3) and
one genotyped as 6/7.
Discussion
The result of our study showed significant correlation
between total plasma bilirubin concentrations and 7/7
genotype. The frequency of 7/7 genotype was 9.8%. Simi-
lar results were reported elsewhere2,8–11.
Significantly higher concentrations of total bilirubin
were found in 7/7 genotype when compared to 6/6 and 6/7
genotypes. Even though some studies reported that sig-
nificant difference exist between the 6/7 and 6/6 geno-
types3 this was not the case in our study.
Moreover, only 6 subjects had elevated total plasma
bilirubin concentrations over the upper limit of the bili-
rubin reference values which indicates that additional
factors could have an important role for the syndrome
manifestation. One out of those six subjects had geno-
type 6/7 which indicated that heterozygous form of the
UGT1A1 promoter genotype could also be associated
with GS.
The frequency of the UGT1A1*28 allele and 7/7 geno-
type is different among ethnic groups. Burchell and
Hume5 summarized the data of several studies showing
that the frequency of 7/7 genotype varies in different
populations as follows: Caucasians up to 11%, in African
population up to 23% and in Asians less than 3%5. Ethnic
groups did not differ only in 7/7 genotype frequencies but
also in total serum bilirubin concentrations. Beutler et
al.12 reported an inverse relation between UGT1A1 pro-
moter genotype and bilirubin concentration in ethnic
groups. Even though the frequency of 7/7 genotype was
very high in African population the average bilirubin
concentration was lower than predicted. According to
this finding it is likely that there are other genetic differ-
ences except UGT1A1 promoter polymorphism in biliru-
bin metabolism between Africans and Caucasians. Fur-
thermore, numerous mutations of UGT1A1 gene were
found in Japanese population but the prevalence of
UGT1A1*28 allele was much lower than in the Cauca-
sian population13. Taken together, all this indicates that
there are differences in TATAA box mutations as well as
difference in genetic basis of GS between different ethnic
groups.
As previously mentioned, the insertion of two addi-
tional TA nucleotides (resulting in seven repeats of TA)
in the TATAA box in both alleles of UGT1A1 gene indi-
cate a close association with reduced expression of the
enzyme B-UGT. Raijmakers et al.9 showed that B-UGT
enzyme activity was significantly higher in 6/6 than in
6/7 and 7/7 genotype. They also noticed that in 6/7 geno-
type enzyme activity was significantly lower than in 6/6
genotype indicating that GS can be associated also with
6/7 genotype.
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TABLE 1.
TOTAL BILIRUBIN CONCENTRATION IN DIFFERENT UGT1A1 GENOTYPES
Genotype N
Total bilirubin concentration mmol/L
Median Range Kruskal-Wallis MANOVA
6/6
6/7
7/7
129
161
33
6.2
6.4
9.02
3.1–16.6
3.1–23.7
2.7–24.7
p<0.001 p<0.001
0,00
1,00
2,00
3,00
4,00
5,00
6,00
7,00
8,00
9,00
10,00
6/6
UGT1A1 genotype
6/7 7/7
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Fig. 2. Total bilirubin concentration in different UGT1A1 geno-
types.
Glucuronidation is an important step in the process of
detoxification, in which the toxic compounds are conju-
gated and eliminated through the bile. UGT1A1 genetic
polymorphism, due to reduced activity of B-UGT en-
zyme, causes reduced glucuronidation of some drugs.
Several investigators reported decreased glucuronida-
tion and elimination of irrinotecan, an anticancer drug,
in GS patients14. Active metabolite of irrinotecan SN-38
is undergoing glucuronidation by B-UGT and forming
the inactive metabolite (SN-38-glucuronide), which is ex-
creted into the bile15. Due to reduced activity of B-UGT,
subjects with GS submitted to anticancer treatment
could be at increased risk of irrinotecan toxicity15. Since
UGT1A1 is responsible for conjugation of some other
drugs and xenobiotics GS subjects could have increased
susceptibility toward those compounds and be at in-
creased risk of toxicity. For example, UGT1A1 was recog-
nized to be one of several UGTs which glucuronidate car-
cinogens including benzo(a)pyrene (polycyclic aromatic
hydrocarbon)16. Thus, subjects with reduced UGT1A1
activity could be at increased risk for developing cancer.
In their study Peterson et al.17 indicated that UGT1A1
activity could be modulated by diet. They reported that
subjects with 7/7 genotype have reduced bilirubin con-
centrations with increased intake of cruciferous vegeta-
bles suggesting that some components of those vegeta-
bles could influence UGT1A1 expression through sig-
naling pathways.
In conclusion, the prevalence of genotype 7/7 in the
population of Croatian pre-scholars is 9.8 % which corre-
lates with the data of some similar Caucasians studies.
Advanced genomic knowledge and technologies as well as
the genetic background of common diseases and syn-
dromes (like those involved in bilirubin metabolism) are
starting to reveal great variety of potential genetic cau-
ses with important influence of environmental factors18.
Considering the fact that UGT1A1*28 is a frequently
occurring mutation in population, it would be suggested
to introduce UGT1A1 genotyping in cases of borderline
hyperbilirubinemia. Moreover, it would help us to distin-
guish whether elevated bilirubin concentrations in some
subjects are the result of UGT1A1 polymorphism or
other disorder of liver metabolism. Furthermore, it would
enable more appropriate dosage adjustment of therapeu-
tic drugs which are metabolized through UGT1A1, in GS
patients.
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FREKVENCIJA GENOTIPOVA UDP-GLUKURONOZILTRANSFERAZE 1A1 POLIMORFIZMA U
PROMOTOR REGIJI GENA U POPULACIJI ZDRAVE DJECE PRED[KOLSKE DOBI U HRVATSKOJ
S A @ E T A K
Povi{ena koncentracija bilirubina u pacijenata s Gilbertovim sindromom (GS) uzrokovana je redukcijom aktivnosti
jetrene bilirubin glukuronoziltransferaze na otprilike 30%. Polimorfizam gena za UGT1A1 s dokinutom ili jako sma-
njenom aktivno{}u enzima UDP-glukuronoziltransferaze (B-UGT) je povezan s Gilbertovim sindromom te drugim vr-
stama hiperbilirubinemije. Genetska osnova GS je insercija dva dodatna TA nukleotida ({to rezultira sedmerostrukim
ponavljanjem TA) u TATA kutiji prisutnoj u proksimalnoj regiji promotora gena za UGT1A1. U ovoj studiji sudjelovalo
je 323 hrvatske djece pred{kolske uzrasti uklju~uju}i 164 dje~aka i 159 djevoj~ica. Statisti~ka analiza pokazala je zna~aj-
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nu razliku u koncentraciji ukupnog bilirubina izme|u genotipova (p<0.001). Nadalje, utvr|ena je statisti~ki zna~ajna
razlika u koncentraciji ukupnog bilirubina izme|u genotipova 6/6 i 7/7 (p<0.001), kao i 6/7 i 7/7 (p<0.001). Povi{ene
koncentracije ukupnog bilirubina u plazmi pokazale su zna~ajnu povezanost sa genotipom 7/7 koji je bio prisutan u
9.8% populacije.
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